These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15571637)

  • 1. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].
    FIELD Study Investigators
    Cardiovasc Diabetol; 2004 Dec; 3():9. PubMed ID: 15571637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?
    Tenenbaum A; Fisman EZ
    Cardiovasc Diabetol; 2004 Dec; 3():10. PubMed ID: 15574199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FIELDS of dreams, fields of tears: a perspective on the fibrate trials.
    Wierzbicki AS
    Int J Clin Pract; 2006 Apr; 60(4):442-9. PubMed ID: 16620358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].
    Scott R; Best J; Forder P; Taskinen MR; Simes J; Barter P; Keech A;
    Cardiovasc Diabetol; 2005 Aug; 4():13. PubMed ID: 16111499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
    Carrington M; Stewart S
    Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role for fibrate therapy in diabetes: evidence before FIELD.
    Vergès B
    Curr Opin Lipidol; 2005 Dec; 16(6):648-51. PubMed ID: 16276243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.
    Vergès B
    Curr Opin Lipidol; 2006 Dec; 17(6):653-8. PubMed ID: 17095910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence.
    Chalmers J; Joshi R; Kengne AP; Ninomiya T; Bi Y; Bompoint S; Billot L; Patel A;
    J Hypertens Suppl; 2008 Sep; 26(3):S21-7. PubMed ID: 19363849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
    Hiukka A; Westerbacka J; Leinonen ES; Watanabe H; Wiklund O; Hulten LM; Salonen JT; Tuomainen TP; Yki-Järvinen H; Keech AC; Taskinen MR
    J Am Coll Cardiol; 2008 Dec; 52(25):2190-7. PubMed ID: 19095138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
    Knopp RH; d'Emden M; Smilde JG; Pocock SJ
    Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The collaborative atorvastatin diabetes study: preliminary results.
    Owen OG
    Int J Clin Pract; 2005 Jan; 59(1):121-3. PubMed ID: 15707477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).
    Wilcox R; Kupfer S; Erdmann E;
    Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Ginsberg HN; Bonds DE; Lovato LC; Crouse JR; Elam MB; Linz PE; O'connor PJ; Leiter LA; Weiss D; Lipkin E; Fleg JL;
    Am J Cardiol; 2007 Jun; 99(12A):56i-67i. PubMed ID: 17599426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS).
    Neil HA; DeMicco DA; Luo D; Betteridge DJ; Colhoun HM; Durrington PN; Livingstone SJ; Fuller JH; Hitman GA;
    Diabetes Care; 2006 Nov; 29(11):2378-84. PubMed ID: 17065671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.